《藍籌業績》創科(00669.HK)中期純利5.24億美元增58% 派息85港仙
創科實業(00669.HK)公布6月止六個月中期業績,營業額63.94億美元,按年增加52%。錄得純利5.24億美元,增長57.9%,每股盈利28.62美仙。中期息85港仙,上年同期派53港仙。
期內,毛利24.65億美元,增加54.3%;毛利率上升58基點至38.6%。每個地區及業務單位均錄得可觀的銷售額增長,其中北美及歐洲分別錄得50.2%和62.3%上升,其他地區增長50%。
上半年,總經營開支19億美元,增加53.2%,佔營業額29.7%;研發開支佔營業額3.1%。營運資金佔銷售額比例18.3%,較目標的20%為低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.